Financial writer discusses Coya Therapeutics, Inc.'s Treg therapies for neurodegenerative diseases like ALS, FTD, and PD.

The US company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, ...

Groundbreaking personalized kidney cancer vaccines show promise in early clinical trials, triggering strong immune responses ...

Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...

A cancer vaccine generated using the cells left over after tumour removal surgery could help to keep patients from ...

The "personalized cancer vaccines" (PCVs) used by the nine patients in the trial were targeted to genes specific to their ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

In a Phase 1 study, nine people with advanced kidney cancer became cancer free after receiving personalized vaccines.

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell ...